No­vo Nordisk launch­es head-to-head tri­al with Eli Lil­ly as weight loss ri­val­ry heats up

As Eli Lil­ly launch­es its new­ly ap­proved weight loss med Zep­bound to much fan­fare, No­vo Nordisk is toss­ing a next-gen can­di­date in the ring.

The Dan­ish phar­ma com­pa­ny is launch­ing a Phase III head-to-head tri­al com­par­ing Zep­bound (tirzepatide) to its ex­per­i­men­tal Ca­griSe­ma, which com­bines No­vo’s block­buster We­govy (semaglu­tide) with the ex­per­i­men­tal long-act­ing amylin ana­log ca­gril­in­tide. The study will en­roll 800 pa­tients, with an es­ti­mat­ed com­ple­tion in the sec­ond half of 2025, ac­cord­ing to a list­ing on clin­i­cal­tri­als.gov.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER